08 Sep
Latest News

Market Access & reimbursement for digital health applications

In Germany, a new market access and reimbursement process for digital health applications (DiGAs) was introduced in early 2020. In our approx. 45-minute webinar, you will learn what this new process looks like and which similar processes may exist in a European comparison. The French expert Guy Eiferman from the Market Access consulting agency Nextep will speak about the French process. The webinar will conclude with a panel discussion on the main differences and similarities between France and Germany as driving forces for digital innovation in Europe.

Register now!!

28 May
Latest News

Webinar: Covid-19 in Europe – Germany ahead of others, but when will the second wave come and how will this potentially look like?

Germany has been seen at the forefront of the Covid-19 control and outcomes. The situation until end May is very promising with a reproduction number below one and new infections below 800 per day. Few hotspots have been identified and lock-down measures have been relaxed to a maximum. However, a core question remains: Not if, but when will a second wave of Covid-19 come and how will this potentially look like.

The MArS Covid-19 task force will present to you some realistic simulation scenarios based on epidemiological evidence.

Register now

19 May
Latest News

New Webinar on Covid-19 and digitalization on May 28 2020

The covid-19 outbreak has had a significant impact on daily life of populations and health care systems. Due to physical distancing as a core policy, digitalization is a main opportunity also in health care. At the same time the new law for digitalization in health care (DiGA) was made effective In Germany.

The MArS Covid-19 task force will show you in this webinar:

  • How digitalization has changed the health care system
  • The different pathways for digitalization solutions to the German market

Register now: Webinars

28 Feb
Latest News

Price negotiation article published – link MArS negotiation boot camp

Price negotiation strategy is most of the times also linked to the available evidence and the potential bet on future data. Gladwell et al. have just published a nice simulation approach with the example in the UK which can also be utilized in the D-A-CH context. For the German AMNOG that approach is also relevant for orphan drugs earlier in the process also with the G-BA and for any pharmaceutical within the price negotiations with the GKV-SV.

The article is available in Value in Health.

MArS has long-lasting experience in (price) negotiations in the D-A-CH regions. We have also developed an internal and successful negotiation boot camp utilizing virtual reality. Contact us for a live demonstration.